Tag: nephrology drugs market demand

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Nephrology Drugs Market Grown from 2024 to 2025?

The market for nephrology drugs has seen substantial growth in recent years, and its size is projected to expand from $16.88 billion in 2024 to $17.86 billion in 2025, a compound annual growth rate (CAGR) of 5.8%. The historical growth in this sector can be credited to a number of factors, including an increase in the prevalence of chronic kidney diseases (CKD), advancements in the process of drug development, increased public awareness and medical diagnoses, government efforts, and amendments to healthcare policies, as well as a rising incidence associated with diabetes.

What Growth Rate Is Anticipated for the Nephrology Drugs Market in the Coming Years?

The market size for nephrology drugs is projected to experience significant expansion in the upcoming years, reaching “$23.04 billion by 2029, with a compound annual growth rate (CAGR) of 6.6%. This projected growth during the forecast period can be accredited to factors such as the development of new therapies and drug innovations, the rise of precision medicine and tailor-made treatment methods, an increase in healthcare spending, the introduction of telehealth and remote patient observation, along with global health initiatives. Noteworthy trends anticipated within the forecast period encompass collaborations and partnerships, technological progress in dialysis, advancements in treatment methods, a growing focus on early diagnosis and intervention, and the incorporation of technology in nephrology management.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10076&type=smp

Who Are the Leading Companies in the Nephrology Drugs Market?

Major companies operating in the nephrology drugs market include AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Amicus Therapeutics, Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Endo Pharmaceuticals plc

What Are the Key Drivers of the Nephrology Drugs Market?

The increasing incidence of chronic kidney disease is anticipated to spur the expansion of the nephrology drugs market. Chronic kidney disease (CKD) involves weakened kidneys that are unable to efficiently purify the blood; because this damage develops over a long period, harmful waste can build up in the body. Nephrology medications are mainly used to improve kidney function and slow the progress of CKD, thus preventing additional damage to the body. This positively affects the growth of the nephrology drug market. For example, data shared in July 2022 by the Centers for Disease Control and Prevention (CDC), a health protection agency based in the U.S., revealed that more than 37 million individuals in the U.S. were diagnosed with CKD, most prevalently among those aged 65 or older (38 percent). Furthermore, the Kidney Foundation of Canada, a non-profit organization, states that 4 million Canadians have kidney diseases, with diabetes accounting for 35 percent of kidney failure cases. These figures are projected to increase in the future. Hence, the mounting incidence of chronic kidney disease is fuelling the expansion of the nephrology drug market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10076&type=smp

What Are the Key Market Segments in the Nephrology Drugs Industry?

The nephrology drugs market covered in this report is segmented –

1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Antihypertensive Agents: Calcium Channel Blockers, Beta-Blockers, Angiotensin II Receptor Blockers (ARBs)

2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa

3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics

4) By ACE Inhibitors: Lisinopril, Enalapril

5) By Antidiabetic Agents: Metformin, Insulin

6) By Other Drugs: Phosphate Binders, Vitamin D Analogues, Renin Inhibitors

What Are the Latest Trends in the Nephrology Drugs Market?

Product innovation is emerging as a crucial trend within the nephrology drug market. To maintain their footing in the market, leading companies are investing in the development and creation of new products and drugs. For instance, in March 2022, Indian pharmaceutical firm Zydus Lifesciences Limited unveiled Oxemia (desidustat) for the treatment of chronic kidney disease (CKD). As an oral hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, Oxemia offers a convenient therapeutic solution for treating anemia and it passed the Phase III clinical trials with approval from the Drug Controller General of India. The trials demonstrated promising results, including safe profiles, hepcidin lowering, improved iron movement, and lessened LDL-C in CKD patients. Importantly, this treatment is affordable and aims to enhance patients’ quality of life and reduce the impact of the disease.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report

What Are the Key Regional Markets in the Nephrology Drugs Industry?

North America was the largest region in the nephrology drug market in 2024.Europe will be the second-largest growing region in the nephrology drug market in 2024. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10076

This Report Delivers Insight On:

1. How big is the nephrology drugs market, and how is it changing globally?

2. Who are the major companies in the nephrology drugs market, and how are they performing?

3. What are the key opportunities and risks in the nephrology drugs market right now?

4. Which products or customer segments are growing the most in the nephrology drugs market?

5. What factors are helping or slowing down the growth of the nephrology drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the nephrology drugs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Key Projections for the CAGR of the Nephrology Drugs Market Size From 2025 to 2034?

In the prior years, there has been significant expansion in the size of the nephrology drugs market. The market, which was valued at $16.88 billion in 2024, is projected to increase to $17.86 billion in 2025, translating to a compound annual growth rate (CAGR) of 5.8%. Several factors contributed to this growth during the historical period. These include the increasing prevalence of chronic kidney diseases (CKD), strides in drug development, heightened awareness and diagnosis, government action, and healthcare policies, as well as the rising incidence of diabetes.

In the coming years, we can anticipate a significant surge in the nephrology drugs market size, which is predicted to reach $23.04 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 6.6%. Contributing factors for this growth over the forecast period include the emergence of innovative therapies and drugs, precision and personalized treatment plans, increased healthcare spending, telehealth, and remote patient services, as well as global health initiatives. Key trends during this period are expected to encompass collaborations, strategic partnerships, technological breakthroughs in dialysis procedures, improvements in treatment strategies, an increased focus on early diagnosis and intervention, and the integration of technology in managing nephrology.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10076&type=smp

What Are the Core Market Drivers Propelling Growth in the Nephrology Drugs Industry?

The nephrology drugs market is anticipated to grow due to the increasing occurrence of chronic kidney disease (CKD). CKD involves impaired kidneys that can’t efficiently purify blood as they’re supposed to, as kidney damage unfolds over a long timeframe. This damage could result in the accumulation of wastes within the body. Nephrology drugs are essentially utilized in managing chronic kidney disease to enhance kidney performance and slow down the progression of the condition, preventing further harm to the body. This leads to an increase in the nephrology drugs market. For example, the Centers for Disease Control and Prevention (CDC), a US-based health protection agency, reported in July 2022 that over 37 million people in the US were identified with chronic kidney disease, predominantly affecting individuals aged 65 years or older (38 percent). Additionally, according to the Kidney Foundation of Canada, a Canada-based non-profit entity, around 4 million Canadians are afflicted with kidney diseases. Diabetic patients account for 35 percent as the main cause of kidney failure. These figures are anticipated to increase in the years to come. Hence, the escalating prevalence of chronic kidney disease is fueling the expansion of the nephrology drugs market.

How Is the Nephrology Drugs Market Segmented?

The nephrology drugs market covered in this report is segmented –

1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Antihypertensive Agents: Calcium Channel Blockers, Beta-Blockers, Angiotensin II Receptor Blockers (ARBs)

2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa

3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics

4) By ACE Inhibitors: Lisinopril, Enalapril

5) By Antidiabetic Agents: Metformin, Insulin

6) By Other Drugs: Phosphate Binders, Vitamin D Analogues, Renin Inhibitors

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=10076&type=smp

Which Regions Are Driving the Next Phase of the Nephrology Drugs Market Growth?

North America was the largest region in the nephrology drug market in 2024.Europe will be the second-largest growing region in the nephrology drug market in 2024. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Market Trends and Innovations Are Shaping the Future of the Nephrology Drugs Industry?

The advancement of product development is a significant trend rising in the nephrology medication market. Key players in this market are introducing novel products and medications to maintain their market presence. For instance, Zydus Lifesciences Limited., a pharmaceutical firm based in India, released Oxemia (desidustat) for chronic kidney disease (CKD) in March 2022. This orally-administered small-molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor serves as a convenient therapeutic solution for anemia treatment and has been validated by the Drug Controller General of India. In Phase III clinical testing, it showed promising safety records, decreased hepcidin, improved iron mobilization, and a drop in LDL-C among CKD patients. Furthermore, by offering affordable treatment and improving patient’s life quality, this contributes to easing the disease’s impact.

View the full report here:

https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report

How Is the Nephrology Drugs Market Defined and What Are Its Core Parameters?

Nephrology drugs, also known as renal drugs, refer to medicines related to kidney care. These drugs are often related to high blood pressure and hypertension. It is used to attempt to enhance kidney function and to slow the disease down, preventing it from doing further harm to the body.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10076

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of the Nephrology Drugs Market?

The increase in chronic kidney disease cases anticipated to fuel the expansion of the market for nephrology drugs. Chronic kidney disease (CKD) is a condition where the kidneys are damaged and cannot effectively perform their function of blood filtration. This damage happens progressively over a prolonged period, which may lead to waste accumulating in the body. The primary purpose of nephrology drugs is to treat chronic kidney disease, enhance the functioning of the kidneys, and slow down the progression of the disease, hence preventing more damage to the body. This scenario thereby stimulates the nephrology drugs market growth. For example, it was reported by the US-based Centers for Disease Control and Prevention (CDC) in July 2022, that over 37 million people in the US have been diagnosed with chronic kidney disease, a condition particularly prevalent in people aged 65 years or older at 38%. Additionally, the Canada-based Kidney Foundation of Canada reported that 4 million Canadians are suffering from kidney diseases. With diabetic patients constituting 35%, they are the prime causes of kidney failure. Thus, the escalating prevalence of chronic kidney disease is spurring the growth of the nephrology drug market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10076&type=smp

#What Are the Key Projections for the CAGR of the Nephrology Drugs Market From 2025 to 2034?

In recent times, there has been a robust expansion in the size of the nephrology drugs market. This growth is projected to continue, seeing an increase from $16.88 billion in 2024 to $17.86 billion in 2025, marking a compound annual growth rate (CAGR) of 5.8%. Factors such as the increasing rates of chronic kidney diseases (CKD), advances in drug creation, heightened awareness and diagnosis, government-driven initiatives, and healthcare policies, along with a rise in diabetes cases, substantially contributed to this historic growth period.

The market for nephrology drugs is projected to experience robust expansion in the coming years, increasing to $23.04 billion by 2029 at a compound annual growth rate (CAGR) of 6.6%. This surge over the forecast period can be associated with the advent of new therapies and drug developments, precision medication, tailored treatment strategies, amplified healthcare expenditures, telehealth, and remote patient supervision, as well as international health strategies. Noteworthy trends during this forecast period encompass collaborations and alliances, technological progress in dialysis, advancements in treatment methods, an increasing focus on early detection and intervention, and technological incorporation in nephrology management.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10076

What Key Market Trends and Innovations Are Shaping the Future of the Nephrology Drugs Industry?

Pioneering new products is a leading trend making waves in the nephrology medicine market. Key businesses in this market are creating fresh and innovative drugs to retain their grip on the market. For instance, Zydus Lifesciences Limited, a pharmaceutical company based in India, unveiled Oxemia (desidustat) in March 2022, a drug for chronic kidney disease (CKD). This orally administered, small-molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor presents a practical treatment alternative for anaemia and has received the green light from the Drug Controller General of India after Phase III clinical trials. The drug has shown to have a sound safety profile, effectively reduces hepcidin, improves iron mobilization, and cuts down LDL-C in patients with chronic kidney disease. Additionally, offering this treatment at a fair price will improve the patients’ quality of life and alleviate the disease’s impact.

Which Companies Are Leading the Charge in Expanding the Nephrology Drugs Market Growth?

Major companies operating in the nephrology drugs market include AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Amicus Therapeutics, Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Endo Pharmaceuticals plc

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report

How is the Global Nephrology Drugs Market Segemented?

The nephrology drugs market covered in this report is segmented –

1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Antihypertensive Agents: Calcium Channel Blockers, Beta-Blockers, Angiotensin II Receptor Blockers (ARBs)

2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa

3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics

4) By ACE Inhibitors: Lisinopril, Enalapril

5) By Antidiabetic Agents: Metformin, Insulin

6) By Other Drugs: Phosphate Binders, Vitamin D Analogues, Renin Inhibitors

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=10076&type=smp

Which Geographics are Influencing the Growth of the Nephrology Drugs Market?

North America was the largest region in the nephrology drug market in 2024.Europe will be the second-largest growing region in the nephrology drug market in 2024. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Gobal Nephrology Drugs Maret 2025, By The Business Research Company:

Drug Delivery Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

Drugs For Erectile Dysfunction Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-erectile-dysfunction-global-market-report

Drugs For Benign Prostatic hypertrophy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the nephrology drugs market grown in recent years?

The market size for nephrology drugs has been witnessing robust growth in the recent past. The market is predicted to grow from $16.88 billion in 2024, to a size of $17.86 billion in 2025, growing at a compound annual growth rate (CAGR) of 5.8%. This significant increase during the historical period can be attributed to factors such as high prevalence of chronic kidney diseases (CKD), advancements in the development of drugs, heightened awareness and diagnostic capabilities, government-driven initiatives, healthcare policies, and an uptick in diabetes cases.

How is the nephrology drugs market size expected to evolve during the forecast period?

Anticipated to witness robust expansion in the forthcoming years, the nephrology drugs market is projected to reach a whopping $23.04 billion by 2029, proliferating at a compound annual growth rate (CAGR) of 6.6%. This upswing during the prediction period is likely due to an emergence of new therapy techniques and advanced drug inventions, precision and custom-made treatment strategies, a rise in health care expenses, remote patient care along with telehealth, and worldwide health endeavours. A few key trends slated for the forecasting period entail collaborations and partnerships, revolutionary advancements in dialysis technology, enhancements in treatment methodologies, a growing focus on early detection and timely intervention, and the technological amalgamation in the management of nephrology.

Get your nephrology drugs market report here!

https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report

Which key drivers are propelling the nephrology drugs market’s growth?

The growth of the nephrology drugs market is anticipated to be spurred by the increasing occurrence of chronic kidney disease (CKD). When kidneys are damaged, they lose their ability to effectively filter blood, leading to a gradual build-up of wastes in the body over time. To combat this, nephrology drugs are used to improve kidney function and halt disease progression, which in turn stimulates the nephrology drug market. For example, the Centers for Disease Control and Prevention (CDC), a health protection agency based in the United States, reported in July 2022 that over 37 million people in the United States had been diagnosed with CKD, most prevalently among people aged 65 or older (38 percent). In addition, according to the Kidney Foundation of Canada, a non-profit organization in Canada, 4 million Canadians are dealing with kidney diseases. It identifies 35 percent of diabetic patients as the main contributors to kidney failure. These numbers are predicted to escalate in the coming years. Hence, the escalating incidence of CKD propels the growth of the nephrology drug market.

What are the market segments in the nephrology drugs industry?

The nephrology drugs market covered in this report is segmented –

1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Antihypertensive Agents: Calcium Channel Blockers, Beta-Blockers, Angiotensin II Receptor Blockers (ARBs)

2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa

3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics

4) By ACE Inhibitors: Lisinopril, Enalapril

5) By Antidiabetic Agents: Metformin, Insulin

6) By Other Drugs: Phosphate Binders, Vitamin D Analogues, Renin Inhibitors

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10076&type=smp

Which leading companies are shaping the growth of the nephrology drugs market?

Major companies operating in the nephrology drugs market include AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Amicus Therapeutics, Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Endo Pharmaceuticals plc

What key trends are currently impacting the nephrology drugs market’s development?

The emergence of product innovation is becoming a significant trend in the nephrology drug market. To maintain their competitive edge, leading companies in this field are coming up with fresh and innovative products and medicines. As an example, Zydus Lifesciences Limited., a pharmaceutical firm based in India, unveiled Oxemia (desidustat), a new drug for chronic kidney disease (CKD), in March 2022. This oral, small-molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor offers an easy-to-use therapeutic solution for anemia treatment. Following Phase III clinical trials, the Drug Controller General of India provided its stamp of approval, recognizing its attractive safety profiles, better regulation of hepcidin, improved iron mobilization, and LDL-C reductions in CKD patients. By offering an affordable treatment option and seeking to enhance patient quality of life, Zydus is taking strides towards easing the burden of this disease.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10076

Which geographic areas are influencing the growth of the nephrology drugs market?

North America was the largest region in the nephrology drug market in 2024.Europe will be the second-largest growing region in the nephrology drug market in 2024. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Drug Delivery Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

Drugs For Erectile Dysfunction Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-erectile-dysfunction-global-market-report

Drugs For Benign Prostatic hypertrophy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: